Mepivacaine Vs. Bupivacaine Spinal for TKA

Medical University of South Carolina (MUSC)

Status: Completed

Conditions: Total Knee Replacement

Treatments: Other: Bupivacaine Spinal; Other: Mepivacaine Spinal

Study type: Interventional

Funder types: Other

Identifiers

NCT05765682

Pro00125382

Details and patient eligibility

About

This study will enroll patients 18-75 years of age who are undergoing elective primary total knee replacement. The patients will be randomized to receive one of two spinal blocks: 1) mepivacaine or 2) bupivacaine. The primary goal is to determine which group arrives at recovery of motor function first. Ultimately, this study will explore if mepivacaine leads to earlier return of motor function and ultimately earlier movement and discharge times following total knee replacement.

Enrollment: 160 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Ages 18-75 years of age
• Undergoing elective primary total knee arthroplasty

Exclusion criteria

• Inability to ambulate or impaired motor function in lower extremities prior to surgery
• Contraindication to spinal anesthetic
• Taking over 30mg oxycodone per day (or calculated MME equivalent)
• Subjects that are unable or choose not to give informed consent
• Known preoperative substance abuse
• Pregnant women
• Allergy to all opioids

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

160 participants in 2 patient groups

Mepivacaine Spinal

Active Comparator group

Description:

Mepivacaine (60 mg: 3ml of 2%) or will be injected into the intrathecal space.

Treatment:

Other: Mepivacaine Spinal

Bupivacaine Spinal

Active Comparator group

Description:

Isobaric bupivacaine (10mg: 2ml or 0.5%) will be injected into the intrathecal space.

Treatment:

Other: Bupivacaine Spinal